Welcome!

Microsoft Cloud Authors: David H Deans, Liz McMillan, Pat Romanski, Janakiram MSV, Jnan Dash

News Feed Item

CareFusion Reports Preliminary First Quarter Fiscal 2013 Results

Provides update on Form 10-K filing

SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- CareFusion Corp. (NYSE: CFN) today reported preliminary results for its first quarter of fiscal 2013, ended Sept. 30, and provided an update on plans to file its Form 10-K for fiscal 2012. 

"We had another quarter of solid strategic progress and strong execution across the company, including balanced contributions from both segments," said Kieran T. Gallahue, chairman and CEO. "Our Medical Systems and Procedural Solutions segments performed in line with our expectations, putting us in a good position as we begin the year.

"While we are not able to provide a full financial update today, we now have a path toward completing the filing of our fiscal 2012 Form 10-K. As our Finance team completes this necessary work, the rest of our organization remains absolutely focused on our customers, as demonstrated in this quarter's results."

As previously disclosed, the company delayed the filing of its Form 10-K for fiscal 2012 to consult with the SEC about its accounting policy for sales-type leases in its Pyxis® medication and supply dispensing product lines.  As a result of these discussions, the company has determined that it will modify the manner in which it applies lease accounting principles to its Pyxis sales-type leases. The company is now in the process of analyzing the impact on its financials. The modified application of lease accounting principles will impact how the company records revenue for its sales-type leases.  As a result, the amount of revenue recorded at the inception of each lease and the amount recorded as finance income during the term of each lease may change. In some cases, more revenue may be recognized at the inception of the lease and, in other cases, more revenue may be recognized as finance income during the lease term.  However, this should not result in any change in the total amount of revenue recognized over the term of a lease. This matter also does not affect CareFusion customers or the underlying fundamentals and cash flows of the company or its Pyxis business.

Until this analysis is complete, CareFusion is unable to report its consolidated financial results. Accordingly, the company today provided selected operating and financial results compared to the quarter ended Sept. 30, 2011. These results are preliminary and remain subject to the completion of the company's quarterly review and the filing of its Form 10-Q for the quarter ended Sept. 30, 2012. Although the company plans to delay the filing of its Form 10-Q with the SEC beyond the Nov. 9 due date, CareFusion intends to file its Form 10-K and Form 10-Q as soon as possible after its accounting analysis is complete.

Medical Systems

Within the Medical Systems segment, revenue for the Infusion Systems business unit was ahead of company expectations, finishing the quarter at $203 million, a 1 percent decline from the prior year period. CareFusion previously said infusion revenue was expected to decline 5 percent during fiscal 2013 following a record year of infusion sales in fiscal 2012.

Revenue for the Respiratory Technologies business unit increased 4 percent from the prior year period to $97 million, driven by continued strength in ventilator sales that was partially offset by weakness in the respiratory diagnostics portfolio. Beginning this quarter, CareFusion is reporting financial results for its ventilation and respiratory diagnostics businesses together to reflect a change in the company's organizational structure.

Dispensing Technologies had another strong quarter, delivering results in line with company expectations. While CareFusion is unable to provide specific financial performance for its Dispensing Technologies business unit until it completes the analysis regarding its sales-type leases, the underlying fundamentals of the business, as well as the competitive landscape, remain unchanged. The company continues to execute well with the rollout of its new product platform and expand its business outside the U.S.

Procedural Solutions

First quarter revenue for the Procedural Solutions segment was $286 million, an increase of 1 percent from the prior year period. Segment profit increased 24 percent to $41 million, a 14 percent increase to $48 million on an adjusted basis.

Within the segment, revenue for the Infection Prevention business unit reached $144 million, a 4 percent increase from the prior year period based on strong sales growth of the company's clinically differentiated preoperative skin preparation and infusion specialty disposables product lines.

Contributions from the June 2012 acquisition of U.K. Medical and growth in the company's clinically differentiated interventional specialties portfolio drove a 3 percent increase in revenue in the Medical Specialties business unit to $80 million from $78 million in the prior year period.

As expected, revenue in the Specialty Disposables business unit declined, closing the quarter at $62 million, or 6 percent lower than the prior year period, as the company transitions its business model and portfolio of products.

Additional financial results

Operating expenses during the quarter totaled $293 million, a decrease of 5 percent from the prior year period. Excluding nonrecurring items and amortization of acquired intangibles, adjusted operating expenses decreased 1 percent to $276 million.

Selling, general and administrative (SG&A) expenses also fell during the quarter to $244 million, an 8 percent decrease from the prior year period. These ongoing cost-savings initiatives helped fund additional investments in research and development, which increased 27 percent to $47 million during the quarter. Adjusted SG&A expenses were $229 million, decreasing 5 percent from $242 million in the prior year period.

Operating cash flow from continuing operations was $78 million, an increase of $75 million over the prior year period.

Recent Highlights

Additional first quarter and recent highlights included:

  • Expanding CareFusion's global reach and respiratory product portfolio with a definitive agreement to acquire Intermed Equipamento Medico Hospitalar Ltda, a privately held, leading respiratory technologies company based in Sao Paulo, Brazil. The acquisition, which is expected to close this month, advances CareFusion's strategy to expand outside of the U.S. through investments that build scale and local capabilities in high-value markets. 
  • Previewing outside of the U.S. the Rowa Dose System, a new, automated concept for continuously packaging medication dosages for individual patients. The development of this new offering was accelerated through the acquisition of an early-stage technology in the fourth quarter of fiscal 2012.
  • Launching a new $500,000 Clinical Excellence grant program from the CareFusion Foundation to help identify and share infection prevention best practices across hospitals and health care facilities nationwide. 
  • Advancing CareFusion's system connectivity and device interoperability strategy by closely integrating the company's Pyxis medication dispensing technologies with Cerner's electronic health record system to help hospitals improve medication management and clinical workflows. This new offering, currently in limited release, is the latest development under a 2010 strategic agreement between CareFusion and Cerner that has also enabled the companies to connect Alaris® infusion pumps and the CareFusion Ventilation System with Cerner's CareAware iBus and Cerner Millennium.
  • Receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for CareFusion's new Snowden-Pencer® take-apart laparoscopic scissors, the latest addition to the company's line of take-apart laparoscopic surgical instruments designed to facilitate sterilization and enhance ergonomics and performance. Currently in limited market release, the new Snowden-Pencer laparoscopic scissors are expected to be commercially available in early 2013.

Conference Call

CareFusion will host a webcast and conference call today at 2 p.m. PST (5 p.m. EST) to discuss the financial and operational results for the first quarter.

To access the call, visit the Investors page at www.carefusion.com. Log on at least 15 minutes before the call begins to register and download or install any necessary audio software.

Investors and other interested parties may also access the call by dialing (800) 599-9795 within the U.S. or (617) 786-2905 from outside the U.S., and use the access code 70745464. A replay of the conference call will be available from 4 p.m. PST (7 p.m. EST) on Nov. 8 through 8:59 p.m. PST (11:59 p.m. EST) on Nov. 15 and can be accessed by dialing (888) 286-8010 in the U.S. or (617) 801-6888 internationally and using the access code 35047396.

About CareFusion Corporation

CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AVEA®, AirLife™ and LTV® series ventilation and respiratory products, ChloraPrep® skin prep products, MedMined® services for data mining surveillance, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 15,000 people across its global operations. More information may be found at http://www.carefusion.com/.

Use of Non-GAAP Financial Measures by CareFusion Corporation

This CareFusion news release and the information contained herein present non-GAAP financial measures that exclude certain amounts, as follows: "adjusted SG&A expenses," which exclude amortization of acquired intangibles, as well as nonrecurring items related to the spinoff; and "adjusted operating expenses," and "adjusted segment profit," which exclude amortization of acquired intangibles, as well as nonrecurring items related to the spinoff and restructuring and acquisition integration charges. The most directly comparable GAAP financial measures for these non-GAAP financial measures are SG&A expenses, operating expenses and segment profit. The company has included below unaudited adjusted financial information for the quarters ended September 30, 2012 and 2011, which includes a reconciliation of GAAP to non-GAAP financial measures.

The company's management uses these non-GAAP financial measures to evaluate the company's performance and provides them to investors as a supplement to the company's reported results, as they believe this information provides additional insight into the company's operating performance by disregarding certain non-recurring items. These non-GAAP financial measures should not be considered in isolation, as a substitute for, or as superior to, financial measures calculated in accordance with GAAP, and the company's financial results calculated in accordance with GAAP and reconciliations to those financial statements should be carefully evaluated. The non-GAAP financial measures used by the company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. While the types of items and charges excluded from the company's non-GAAP financial measures may occur in the future, the company's management believes that they are not reflective of the day-to-day offering of its products and services and relate more to strategic, multi-year corporate actions, without predictable trends, or discrete and unusual or infrequent transactions that are not indicative of future operations or business trends. 

Cautions Concerning Forward-looking Statements

The CareFusion news release and the information contained herein present forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. The matters discussed in these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in CareFusion's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: the modified application of lease accounting principles to our sales-type leases and the potential impact on our reported financial results and financial guidance; the timing for filing our Form 10-K for fiscal 2012 and Form 10-Q for the first quarter of fiscal 2013; we may be unable to effectively enhance our existing products or introduce and market new products or may fail to keep pace with advances in technology; we are subject to complex and costly regulation; cost containment efforts of our customers, purchasing groups, third-party payers and governmental organizations could adversely affect our sales and profitability; current economic conditions have and may continue to adversely affect our results of operations and financial condition; we may be unable to realize any benefit from our cost reduction and restructuring efforts and our profitability may be hurt or our business otherwise might be adversely affected; we may be unable to protect our intellectual property rights or may infringe on the intellectual property rights of others; defects or failures associated with our products and/or our quality system could lead to the filing of adverse event reports, recalls or safety alerts and negative publicity and could subject us to regulatory actions; we are currently operating under an amended consent decree with the FDA and our failure to comply with the requirements of the amended consent decree may have an adverse effect on our business; and our success depends on our key personnel, and the loss of key personnel or the transition of key personnel, including our chief executive officer, could disrupt our business. The CareFusion news release and the information contained herein reflect management's views as of Nov. 8, 2012. Except to the limited extent required by applicable law, CareFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CAREFUSION CORPORATION

SELECTED FINANCIAL DATA1

(UNAUDITED) 


















Quarter Ended
September 30,

Percent

(in millions)

2012

2011

Change







REVENUE:






Medical Systems2





Infusion Systems

$ 203

$ 206

(1) %


Respiratory Technologies3

97

93

4


Other


7

6

17








Procedural Solutions4





Infection Prevention 

$ 144

$ 138

4 %


Medical Specialties

80

78

3


Specialty Disposables

62

66

(6)


   Total Procedural Solutions

$ 286

$ 282

1







OPERATING EXPENSES:





Selling, General and Administrative Expenses

$ 244

$ 264

(8) %


Research and Development Expenses

47

37

27


Restructuring and Acquisition Integration Charges

2

7

(71)







OTHER ITEMS:






Interest Expense and Other, Net 

$ 20

$ 25

(20) %


Loss from Discontinued Operations, Net of Tax

(5)

(2)

150













WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:





Basic


221.9

223.8



Diluted


224.4

226.3














Adjusted Financial Measures:5



Operating Expenses

$ 276

$ 279


____________











1

All results are preliminary and remain subject to the completion of the company's quarterly review and the filing of its Form 10-Q for the quarter ended Sept. 30, 2012, including the completion of the company's analysis regarding its Dispensing sales-type leases, as discussed above.


2

Revenue for the Dispensing Technologies business unit intentionally omitted. As discussed above, until the analysis regarding the company's Dispensing sales-type leases is complete, the company is unable to report the financial results for its Dispensing Technologies business.


3

In July, 2012, the company began managing its Respiratory Diagnostics business as part of its Respiratory Technologies business unit within the Medical Systems reporting segment. Previously, the Respiratory Diagnostics business had been reported in Procedural Systems as Other. Prior period financials have been reclassified to conform to the current presentation.


4

Reflects the impact of businesses reclassified to discontinued operations.


5

Adjusted financial measures are non-GAAP measures that exclude certain nonrecurring items, as discussed above under Use of Non-GAAP Financial Measures. These measures are reconciled to comparable GAAP measures in the Reconciliation of Non-GAAP Financial Measures included on the following page.


 

CAREFUSION CORPORATION

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES1

(UNAUDITED)











Adjusted Financial Data:






Segment Profit 





Procedural

SG&A

Operating

(in millions)

Solutions

Expenses5

Expenses5,6






Quarter Ended September 30, 2012




GAAP


$ 41

$ 244

$ 293

   Restructuring and Acquisition Integration2

1

-

(2)

   Amortization of acquired intangibles4

6

(15)

(15)

Adjusted


$ 48

$ 229

$ 276






Quarter Ended September 30, 2011




GAAP


$ 33

$ 264

$ 308

   Restructuring and Acquisition Integration2

2

-

(7)

   Spinoff3

2

(4)

(4)

   Amortization of acquired intangibles4

5

(18)

(18)

Adjusted


$ 42

$ 242

$ 279

____________




1

All results are preliminary and remain subject to the completion of the company's quarterly review and the filing of its Form 10-Q for the quarter ended Sept. 30, 2012, including the completion of the company's analysis regarding its Dispensing sales-type leases, as discussed above.


2

Restructuring and acquisition integration charges primarily relate to nonrecurring expenses associated with closing and consolidating facilities, as well as rationalizing headcount, and aligning operations.


3

Spinoff charges primarily relate to nonrecurring incremental expenses associated with our spinoff from Cardinal Health, Inc.


4

Amortization of acquired intangibles relate to the non-cash expenses associated with amortization of identifiable intangible assets of acquired businesses.


5

Reflects company expenses on a consolidated basis.


6

Operating expenses consist of selling, general and administrative, research and development, and restructuring and acquisition integration expenses.

SOURCE CareFusion Corp.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
SYS-CON Events announced today that Outlyer, a monitoring service for DevOps and operations teams, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Outlyer is a monitoring service for DevOps and Operations teams running Cloud, SaaS, Microservices and IoT deployments. Designed for today's dynamic environments that need beyond cloud-scale monitoring, we make monitoring effortless so you ...
My team embarked on building a data lake for our sales and marketing data to better understand customer journeys. This required building a hybrid data pipeline to connect our cloud CRM with the new Hadoop Data Lake. One challenge is that IT was not in a position to provide support until we proved value and marketing did not have the experience, so we embarked on the journey ourselves within the product marketing team for our line of business within Progress. In his session at @BigDataExpo, Sum...
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, will discuss the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information,
China Unicom exhibit at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. China United Network Communications Group Co. Ltd ("China Unicom") was officially established in 2009 on the basis of the merger of former China Netcom and former China Unicom. China Unicom mainly operates a full range of telecommunications services including mobile broadband (GSM, WCDMA, LTE FDD, TD-LTE), fixed-line broadband, ICT, data communica...
With the introduction of IoT and Smart Living in every aspect of our lives, one question has become relevant: What are the security implications? To answer this, first we have to look and explore the security models of the technologies that IoT is founded upon. In his session at @ThingsExpo, Nevi Kaja, a Research Engineer at Ford Motor Company, will discuss some of the security challenges of the IoT infrastructure and relate how these aspects impact Smart Living. The material will be delivered i...
Apache Hadoop is emerging as a distributed platform for handling large and fast incoming streams of data. Predictive maintenance, supply chain optimization, and Internet-of-Things analysis are examples where Hadoop provides the scalable storage, processing, and analytics platform to gain meaningful insights from granular data that is typically only valuable from a large-scale, aggregate view. One architecture useful for capturing and analyzing streaming data is the Lambda Architecture, represent...
As organizations realize the scope of the Internet of Things, gaining key insights from Big Data, through the use of advanced analytics, becomes crucial. However, IoT also creates the need for petabyte scale storage of data from millions of devices. A new type of Storage is required which seamlessly integrates robust data analytics with massive scale. These storage systems will act as “smart systems” provide in-place analytics that speed discovery and enable businesses to quickly derive meaningf...
Your homes and cars can be automated and self-serviced. Why can't your storage? From simply asking questions to analyze and troubleshoot your infrastructure, to provisioning storage with snapshots, recovery and replication, your wildest sci-fi dream has come true. In his session at @DevOpsSummit at 20th Cloud Expo, Dan Florea, Director of Product Management at Tintri, will provide a ChatOps demo where you can talk to your storage and manage it from anywhere, through Slack and similar services ...
SYS-CON Events announced today that Ocean9will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Ocean9 provides cloud services for Backup, Disaster Recovery (DRaaS) and instant Innovation, and redefines enterprise infrastructure with its cloud native subscription offerings for mission critical SAP workloads.
The taxi industry never saw Uber coming. Startups are a threat to incumbents like never before, and a major enabler for startups is that they are instantly “cloud ready.” If innovation moves at the pace of IT, then your company is in trouble. Why? Because your data center will not keep up with frenetic pace AWS, Microsoft and Google are rolling out new capabilities In his session at 20th Cloud Expo, Don Browning, VP of Cloud Architecture at Turner, will posit that disruption is inevitable for c...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
SYS-CON Events announced today that Conference Guru has been named “Media Sponsor” of SYS-CON's 20th International Cloud Expo, which will take place on June 6–8, 2017, at the Javits Center in New York City, NY. A valuable conference experience generates new contacts, sales leads, potential strategic partners and potential investors; helps gather competitive intelligence and even provides inspiration for new products and services. Conference Guru works with conference organizers to pass great dea...
SYS-CON Events announced today that Technologic Systems Inc., an embedded systems solutions company, will exhibit at SYS-CON's @ThingsExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Technologic Systems is an embedded systems company with headquarters in Fountain Hills, Arizona. They have been in business for 32 years, helping more than 8,000 OEM customers and building over a hundred COTS products that have never been discontinued. Technologic Systems’ pr...
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From ...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
SYS-CON Events announced today that Telecom Reseller has been named “Media Sponsor” of SYS-CON's 20th International Cloud Expo, which will take place on June 6–8, 2017, at the Javits Center in New York City, NY. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
SYS-CON Events announced today that Loom Systems will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2015, Loom Systems delivers an advanced AI solution to predict and prevent problems in the digital business. Loom stands alone in the industry as an AI analysis platform requiring no prior math knowledge from operators, leveraging the existing staff to succeed in the digital era. With offices in S...
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 20th Cloud Expo, which will take place on June 6-8, 2017 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 add...